பராமரிப்பு உலகளாவிய ஆண்டிமைக்ரோபியல் எதிர்ப்பு கண்டுபிடிப்பு நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Basilea awarded CARB-X grant of up to USD 2 7 million to develop novel-class antibiotic
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Basilea awarded CARB-X grant of up to USD 2 7 million to develop novel-class antibiotic
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Basilea awarded CARB-X grant of up to USD 2 7 million to develop novel-class antibiotic
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic
on May 11 2021 6:00 AM
Test will detect infection of chlamydia and gonorrhoea and determine antimicrobial susceptibility to easy-to-access antibiotics within 60 minutes
SYDNEY (BUSINESS WIRE) #AntimicrobialStewardship SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting research and development to address the rising threat of drug-resistant bacteria. SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones. Funds will be used to develop a rapid test for the combined detection of
/ April 20, 2021 /
Baebies, a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, announced today that CARB-X has awarded the company up to $11.6 million in non-dilutive funding. This funding will support the development of a near-patient and rapid diagnostic platform for sepsis - specially focused on addressing the unique needs of neonatal and pediatric populations.
The CARB-X award consists of $3.9 million in initial funding with up to $7.7 million of milestone-based funding. CARB-X, a global non-profit partnership, provides funding and support for projects that target drug-resistant bacteria deemed Serious or Urgent on the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Resistant Threats list or Critical or High on the World Health Organization s Priority Bacterial Pathogens list.